Results 21 to 30 of about 27,657 (222)

Protective effect of rosiglitazone on microscopic and oxidative stress parameters of ram sperm after freeze-thawing

Scientific Reports, 2022
The purpose of this study was to investigate the effects of rosiglitazone on ram semen after cryopreservation on the quality of thawed sperm. Sperm motility, membrane functionality, viability, total abnormality, acrosome membrane integrity, mitochondrial
Mahdieh Mehdipour, Hossein Daghigh-Kia, Abouzar Najafi, Zohreh Mehdipour, Hossein Mohammadi   +4 more
doaj   +1 more source

Inhibitory effect and mechanism of Rosiglitazone on M1 type polarization of central microglia in intracerebral hemorrhage mice based on JNK/STAT3 signaling pathway

Brain and Behavior, 2023
Background Intracerebral hemorrhage (ICH) seriously threatens the health of people. In addition, microglia M1 polarization was confirmed to be involved in the progression of ICH.
Chenglei Chao, Yinghui Li, Quan Li, Guofeng Wu   +3 more
doaj   +1 more source

Rosiglitazone RECORD study: glucose control outcomes at 18 months. [PDF]

, 2007
AIMS: To compare glucose control over 18 months between rosiglitazone oral combination therapy and combination metformin and sulphonylurea in people with Type 2 diabetes.
Beck-Nielsen, H, Jones, N P, Home, PD, Hanefeld, M, Gomis, R, Pocock, SJ, Pocock, S J, Komajda, M, Jones, NP, Study Group, RECORD, Curtis, P, RECORD Study Group, Home, P D   +12 more
core   +1 more source

Rosiglitazone Suppresses In Vitro Seizures in Hippocampal Slice by Inhibiting Presynaptic Glutamate Release in a Model of Temporal Lobe Epilepsy.

PLoS ONE, 2015
Peroxisomal proliferator-activated receptor gamma (PPARγ) is a nuclear hormone receptor whose agonist, rosiglitazone has a neuroprotective effect to hippocampal neurons in pilocarpine-induced seizures.
Shi-Bing Wong, Sin-Jhong Cheng, Wei-Chen Hung, Wang-Tso Lee, Ming-Yuan Min   +4 more
doaj   +1 more source

Rosiglitazone evaluated for cardiovascular outcomes - An interim analysis [PDF]

, 2007
BACKGROUND: A recent meta-analysis raised concern regarding an increased risk of myocardial infarction and death from cardiovascular causes associated with rosiglitazone treatment of type 2 diabetes. METHODS: We conducted an unplanned interim analysis of
McMurray, JJV, Beck-Nielsen, H, Jones, Nigel P, Home, PD, Hanefeld, M, Home, Philip D, Gomis, R, Pocock, Stuart J, McMurray, John JV, Beck-Nielsen, Henning, Hanefeld, Markolf, Pocock, SJ, Komajda, M, Jones, NP, Study Group, RECORD, Komajda, Michel, Grp, RS, Gomis, Ramón, RECORD Study Group, McMurray, John J V   +19 more
core   +1 more source

Effect of the addition of rosiglitazone to metformin or sulfonylureas versus metformin/sulfonylurea combination therapy on ambulatory blood pressure in people with type 2 diabetes: a randomized controlled trial (the RECORD study). [PDF]

, 2008
BACKGROUND: Hypertension and type 2 diabetes are common co-morbidities. Preliminary studies suggest that thiazolidinediones reduce blood pressure (BP).
Hanefeld Markolf, Jones, Nigel P, Beck-Nielsen Henning, For The RECORD Study Group, Home, Philip D, Jones Nigel P, Ramon Gomis, Beck-Nielsen, Henning, Curtis, Paula, Stuart J Pocock, Komajda Michel, Pocock Stuart J, Michel Komajda, Curtis Paula, Andrew Zambanini, Nigel P Jones, Zambanini, Andrew, Henning Beck-Nielsen, Philip D Home, Markolf Hanefeld, Paula Curtis, Pocock, Stuart J, Hanefeld, Markolf, Gomis, Ramon, Gomis Ramon, Study Group, RECORD, Komajda, Michel, Home Philip D, Zambanini Andrew, RECORD Study Group   +29 more
core   +1 more source

CMHX008, a novel peroxisome proliferator-activated receptor γ partial agonist, enhances insulin sensitivity in vitro and in vivo. [PDF]

PLoS ONE, 2014
The peroxisome proliferator-activated receptor γ (PPARγ) plays an important role in adipocyte differentiation and insulin sensitivity. Its ligand rosiglitazone has anti-diabetic effect but is frequently accompanied with some severe unwanted effects.
Yue Ming, Xiangnan Hu, Ying Song, Zhiguo Liu, Jibin Li, Rufei Gao, Yuyao Zhang, Hu Mei, Tingwang Guo, Ling Xiao, Bochu Wang, Chaodong Wu, Xiaoqiu Xiao   +12 more
doaj   +1 more source

Leukemia and rosiglitazone

Saudi Pharmaceutical Journal, 2016
The article titled “Can an oral antidiabetic (rosiglitazone) be of benefit in leukemia treatment?” written by Cetinkalp et al. and published in one of the recent issues of your journal was quite interesting (Cetinkalp et al., 2015). Here, we would like to emphasize some points. Pan et al.
Irfan Yavasoglu, Gurhan Kadikoylu, Zahit Bolaman   +2 more
openaire   +3 more sources

Effects of Sulfonylureas on Peroxisome Proliferator-Activated Receptor γ Activity and on Glucose Uptake by Thiazolidinediones [PDF]

Diabetes & Metabolism Journal, 2011
BackgroundSulfonylurea primarily stimulates insulin secretion by binding to its receptor on the pancreatic β-cells. Recent studies have suggested that sulfonylureas induce insulin sensitivity through peroxisome proliferator-activated receptor γ (PPARγ ...
Kyeong Won Lee, Yun Hyi Ku, Min Kim, Byung Yong Ahn, Sung Soo Chung, Kyong Soo Park   +5 more
doaj   +1 more source

Direct rosiglitazone action on steroidogenesis and proinflammatory factor production in human granulosa-lutein cells

Reproductive Biology and Endocrinology, 2009
Background Ovarian granulosa cells are the predominant source of estradiol and progesterone biosynthesis in vivo. Rosiglitazone, a synthetic agonist of the peroxisome proliferator-activated receptor gamma (PPAR gamma), is applied as the treatment of ...
Wang Yongwei, Wang Jian, Cheng Linan, Chen Junling, Sun Xiaoxi, Chen Qiuju, Sun Zhaogui   +6 more
doaj   +1 more source